Skip to main content
HCPCS J1745 · Level II · Part B drug

J1745: infliximab (Remicade), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J1745

Billing unit
10 MG
Infliximab not biosimil 10mg
ASP payment limit
$29.856
October 2026; -5.2% vs July 2026
Practitioner MUE
150
MAI 3
OPPS status
SI K
APC 7043
NCCI exposure
no PTP pairs
Coverage articles
2
9 states

TL;DR

HCPCS J1745 is the Level II code for Injection, infliximab, excludes biosimilar, 10 mg, billed per 10 MG. The Medicare Part B ASP payment limit for October 2026 is $29.856 per billing unit, down 5.2% from July 2026. The practitioner MUE allows up to 150 units per date of service (MAI 3), so a full 150-unit day is $4,478.40 at the current limit. Under OPPS it carries status indicator K in APC 7043. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. The 10 mg billing unit means doses are reported in multiples of ten milligrams, with any remainder rounded per contractor policy; mismatched units against the NDC quantity trigger MUE and NDC-unit edits. Other HCPCS codes whose descriptor names infliximab: Q5103 (biosimilar infliximab-dyyb (Inflectra) from Pfizer Inc); Q5104 (biosimilar infliximab-abda (Renflexis) from Organon LLC); Q5121 (biosimilar infliximab-axxq (Avsola) from Amgen Inc). The ASP crosswalk maps 2 NDCs to it, sold as Remicade, Infliximab by Janssen Biotech, Inc. 2 Medicare coverage articles list the code across 9 states, including A52423.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J1745 at $29.856 per 10 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $31.479 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J1745
QuarterPayment limitPerCoinsurance
October 2026$29.85610 MG20%
July 2026$31.47910 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 2 NDCs from 1 labeler to J1745. Report the NDC in the claim's drug segment and bill the number of J1745 units that equals the quantity administered divided by 10 MG; the last column gives units per full package.

NDCs that crosswalk to J1745
NDCDrug nameLabelerPackage sizeBilling units / package
57894-0030-01RemicadeJanssen Biotech, Inc.1 × 110
57894-0160-01InfliximabJanssen Biotech, Inc.1 × 110

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J1745. For practitioners the limit is 150 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J1745 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services1503 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital1503 Date of Service Edit: ClinicalPrescribing Information
DME supplier03 Date of Service Edit: ClinicalCMS Policy

MUE for J1745 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J1745 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J1745 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J1745 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

2 current Medicare Administrative Contractor articles list J1745 in their HCPCS tables, covering 9 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J1745
ArticleTitleContractor(s)StatesRelated LCD
A52423Billing and Coding: Infliximab and biosimilarsWellpoint FederalCT IL MN NY WIL33394
A56432Billing and Coding: InfliximabPalmetto GBANC SC VA WVL35677

Diagnoses Medicare contractors cover for J1745

2 billing and coding articles attach a covered diagnosis list to J1745: 692 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for J1745
ICD-10-CMDescription (FY2027)Articles covering
K50.00Crohn's disease of small intestine without complications2 of 2
K50.011Crohn's disease of small intestine with rectal bleeding2 of 2
K50.012Crohn's disease of small intestine with intestinal obstruction2 of 2
K50.013Crohn's disease of small intestine with fistula2 of 2
K50.014Crohn's disease of small intestine with abscess2 of 2
K50.018Crohn's disease of small intestine with other complication2 of 2
K50.019Crohn's disease of small intestine with unspecified complications2 of 2
K50.10Crohn's disease of large intestine without complications2 of 2
K50.111Crohn's disease of large intestine with rectal bleeding2 of 2
K50.112Crohn's disease of large intestine with intestinal obstruction2 of 2
K50.113Crohn's disease of large intestine with fistula2 of 2
K50.114Crohn's disease of large intestine with abscess2 of 2
K50.118Crohn's disease of large intestine with other complication2 of 2
K50.119Crohn's disease of large intestine with unspecified complications2 of 2
K50.80Crohn's disease of both small and large intestine without complications2 of 2
677 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J1745 are counted here. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J1745, by article
ArticleContractorGroups that applyCovered codes for J1745Full list
A52423Wellpoint Federalone list for every code in the article619On LCD L33394
A56432Palmetto GBAone list for every code in the article406On LCD L35677

Local coverage policies that list J1745

2 active Local Coverage Determinations list J1745 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J1745 carries status indicator K and is assigned to APC 7043, with a published national unadjusted payment of $29.856. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J1745 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $29.86 per 10 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J1745 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J1745

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J1745

What does HCPCS code J1745 describe?

J1745 is defined by CMS as "Injection, infliximab, excludes biosimilar, 10 mg". Each billing unit represents 10 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J1745 a CPT code?

No. J1745 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as infliximab (Remicade); CPT codes are five-character codes maintained by the AMA. On a Part B claim J1745 reports the drug itself in 10 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J1745 in October 2026?

The ASP-based payment limit is $29.856 per 10 MG, with 20% beneficiary coinsurance. The July 2026 limit was $31.479. Commercial payers use their own fee schedules.

How many units of J1745 can be billed per day?

The practitioner Medically Unlikely Edit is 150 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J1745?

The October 2026 ASP crosswalk lists 2 NDCs from 1 labeler: Remicade (Janssen Biotech, Inc.); Infliximab (Janssen Biotech, Inc.). For example NDC 57894-0030-01 (package size 1) equals 10 billing units of J1745.

Does J1745 have NCCI bundling edits?

No active practitioner PTP pairs list J1745 as a column-1 or column-2 code in the v323r0 release.

J1745 vs Q5103: what is the difference?

Both are HCPCS Level II codes whose descriptor names infliximab. What sets Q5103 apart: biosimilar infliximab-dyyb (Inflectra) from Pfizer Inc. J1745 is billed per 10 mg, limit $29.856, MUE 150; Q5103 is billed per 10 mg, limit $28.456, MUE 150. Report the code whose descriptor matches the product and setting in the record.

J1745 vs Q5104: what is the difference?

Both are HCPCS Level II codes whose descriptor names infliximab. What sets Q5104 apart: biosimilar infliximab-abda (Renflexis) from Organon LLC. J1745 is billed per 10 mg, limit $29.856, MUE 150; Q5104 is billed per 10 mg, limit $25.649, MUE 150. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention J1745?

2 current Billing and Coding Articles in the Medicare Coverage Database list J1745, covering 9 states: A52423 (Billing and Coding: Infliximab and biosimilars); A56432 (Billing and Coding: Infliximab).

What diagnosis codes support J1745?

2 Medicare billing and coding articles list 692 covered ICD-10-CM codes for J1745 between them, for example K50.00 (Crohn's disease of small intestine without complications); K50.011 (Crohn's disease of small intestine with rectal bleeding); K50.012 (Crohn's disease of small intestine with intestinal obstruction); K50.013 (Crohn's disease of small intestine with fistula); K50.014 (Crohn's disease of small intestine with abscess). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.